Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

With immunotherapy innovations for cancer treatment, in particular chimeric antigen receptor (CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage their toxicities are required. Anti-CD19 CAR T-cell therapy has revolutionized the treatment of relapsed/refractory pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Riegler, Lara L, Jones, Gavin P, Lee, Daniel W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400118/
https://www.ncbi.nlm.nih.gov/pubmed/30880998
http://dx.doi.org/10.2147/TCRM.S150524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400118/
https://www.ncbi.nlm.nih.gov/pubmed/30880998
http://dx.doi.org/10.2147/TCRM.S150524

Ejemplares similares